Prof. dr. M.J. Kersten MD publications


Publications Prof. dr. M.J. Kersten MD

Main activities
Patient care, Research
Biology and treatment of lymphoma, with an emphasis on early clinical trials
Focus of research

Marie José Kersten is a professor of hematology and head of the department of Hematology at the Academic Medical Center in Amsterdam. B cell malignancies are the main focus of research in this department, which together with the departments of Pathology and Experimental Immunology forms the basis for the LYMMCARE Institute (Lymphoma and Myeloma Center Amsterdam). Marie José Kersten is involved in several research projects and she is the principal investigator for several phase I/II clinical trials focusing on the biology and treatment of NHL, Waldenstrom’s macroglobulinemia and Hodgkin lymphoma. She has recently been appointed as chair of the newly established EHA (European Hematology Association) Scientific Working Group Lymphoma. She is the co-chair of the HOVON (Hemato-Oncologie Volwassenen Nederland) Lymphoma Working Party, and a co-founder and member of the Board of the Lunenburg Lymphoma Phase I/II Consortium (LLPC). The main focus of the LLPC is to perform early clinical trials (from first-in-man trials to early phase II trials) in patients with lymphoma. She is also an active member of the Lunenburg Lymphoma Biomarker Consortium (LLBC), the European Waldenstrom’s Macroglobulinemia Consortium (EWMC) and the HOVON Myeloma Working Party. Another research theme within LYMMCARE is to better understand the biology underlying tumor growth, progression and treatment resistance (in lymphoma, Waldenstrom's macroglobulinemia and multiple myeloma). This research is done in collaboration with the pathology department at the AMC (Pals/Spaargaren).


  • Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ, Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. LANCET HAEMATOL 2018;5 (4):e170-e180 [PubMed]
  • Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ , Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P, Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial. LEUKEMIA 2018;32 (2):383-390 [PubMed]
  • Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, van Imhoff G, Nijland M, Tonino S, Hutchings M, Spiering M, Liu R, van Tinteren H, Kersten MJ, Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study. HAEMATOLOGICA 2018;ahead of print [PubMed]
  • Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ , Tedeschi A, Buske C, Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANN ONCOL 2018;29 (4):41-50 [PubMed]
  • Kater AP, Tonino SH, Spiering M, Chamuleau MED, Liu R, Adewoye AH, Gao J, Dreiling L, Xin Y, Doorduijn JK, Kersten MJ, Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies. BLOOD CANCER J 2018;8 (2):16 [PubMed]
  • Koens L , van de Ven PM, Hijmering NJ, Kersten MJ, Diepstra A, Chamuleau M, de Jong D, Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment. HISTOPATHOLOGY 2018;73 (3):473-482 [PubMed]
  • Nijland ML, Koens L , Pals ST, ten Berge IJM, Bemelman FJ, Kersten MJ, Clinicopathological characteristics of T-cell non-Hodgkin lymphoma arising in patients with immunodeficiencies: a single-center case series of 25 patients and a review of the literature. HAEMATOLOGICA 2018;103 (3):486-496 [PubMed]
  • Oosten LEM, Chamuleau MED, Thielen FW, de Wreede LC, Siemes C, Doorduijn JK, Smeekes OS, Kersten MJ , Hardi L, Baars JW, Demandt AMP, Stevens WBC, Nijland M, van Imhoff GW, Brouwer R, Uyl-de Groot CA, Kluin PM, de Jong D, Veelken H, Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. ANN HEMATOL 2018;97 (2):255-266 [PubMed]
  • Persoon S. Physical exercise in patients treated with hematopoietic stem cell transplantation. S.l.: s.n.; 2018. 184p. ISBN 978-94-90791-62-9 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Kersten MJ , Chin A Paw MJM; copromotor(s): Buffart LM, Nollet F)
  • Persoon S, Buffart LM, Chinapaw MJM, Nollet F, Frings-Dresen MH, Koning S, Kersten MJ , Tamminga SJ, Return to work experiences of patients treated with stem cell transplantation for a hematologic malignancy. SUPPORT CARE CANCER 2018;ahead of print [PubMed]
  • Persoon S, Chinapaw MJM, Buffart LM, Brug J, Kersten MJ , Nollet F, Lessons learnt from a process evaluation of an exercise intervention in patients treated with autologous stem cell transplantation. EUR J CANCER CARE 2018;27 (1):e12779 [PubMed]
  • Ren Z, van Andel H, de Lau W, Hartholt RB, Maurice MM, Clevers H, Kersten MJ, Spaargaren M, Pals ST, Syndecan-1 promotes Wnt/beta-catenin signaling in multiple myeloma by presenting Wnts and R-spondins. BLOOD 2018;131 (9):982-994 [PubMed]
  • Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, Veelken H, van Eijk R, Kraan W, Kersten MJ, van den Brand M, Stevens WBC, de Jong D, Abdul Hamid M, Tanis BC, Posthuma EFM, Nijland M, Diepstra A, Pals ST, Cleven AHG, Vermaat JSP, High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma. BLOOD 2018;131 (18):2086-2089 [PubMed]
  • Stuij SM, Labrie NHM, van Dulmen S, Kersten MJ, Christoph N, Hulsman RL, Smets E [Contributors: Drossaert S, de Haes H, Pieterse A, van Weert J]] , Developing a digital communication training tool on information-provision in oncology: uncovering learning needs and training preferences. BMC MED EDUC 2018;18 (1):220 [PubMed]
  • Sweegers MG, Altenburg TM, Brug J, May AM, van Vulpen JK, Aaronson NK, Arbane G, Bohus M, Courneya KS, Daley AJ, Galvao DA, Garrod R, Griffith KA, van Harten WH, Hayes SC, Herrero-Román F, Kersten MJ, Lucia A, McConnachie A, van Mechelen W, Mutrie N, Newton RU, Nollet F, Potthoff K, Schmidt ME, Schmitz KH, Schulz KH, Sonke G, Steindorf K, Stuiver MM, Taaffe DR, Thorsen L, Twisk JW, Velthuis MJ, Wenzel J, Winters-Stone KM, Wiskemann J, Chin A Paw MJ, Buffart LM, Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data. BRIT J SPORT MED 2018;ahead of print [PubMed]
  • van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KSG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM, Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. LANCET HAEMATOL 2018;5 (10):e479-e492 [PubMed]
  • van Sandwijk MS, Al Arashi D, van de Hare FM, van der Torren JMR, Kersten MJ, Bijlsma JA, ten Berge IJM, Bemelman FJ, Fatigue, anxiety, depression and quality of life in kidney transplant recipients, haemodialysis patients, patients with a haematological malignancy and healthy controls. NEPHROL DIAL TRANSPL 2018;ahead of print [PubMed]
  • Vos JM, Notermans NC, D'Sa S, Lunn MP, van der Pol WL, Kraan W, Reilly MM, Chalker J, Gupta R, Kersten MJ, Pals ST, Minnema MC, High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy. J NEUROL NEUROSUR PS 2018;89 (9):1007-+ [PubMed]


  • Buffart LM, Kalter J, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, May AM, Galvão DA, Chinapaw MJ, Steindorf K, Irwin ML, Stuiver MM, Hayes S, Griffith KA, Lucia A, Mesters I, van Weert E, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M, Thorsen L, Schulz KH, Short CE, James EL, Plotnikoff RC, Arbane G, Schmidt ME, Potthoff K, van Beurden M, Oldenburg HS, Sonke GS, van Harten WH, Garrod R, Schmitz KH, Winters-Stone KM, Velthuis MJ, Taaffe DR, van Mechelen W, Kersten MJ, Nollet F, Wenzel J, Wiskemann J, Verdonck-de Leeuw IM, Brug J, Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs. CANCER TREAT REV 2017;52:91-104 [PubMed]
  • Doorduijn JK, van Imhoff GW, van der Holt B, Schouten HC, Schaafsma MR, MacKenzie MA, Baars JW, Kersten MJ, Lugtenburg PJ, van den Bent MJ, Enting RH, Spoelstra FM, Poortmans P, Bromberg JEC, Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. HEMATOL ONCOL 2017;35 (4):497-503 [PubMed]
  • D'Sa S, Kersten MJ, Castillo JJ, Dimopoulos M, Kastritis E, Laane E, Leblond V, Merlini G, Treon SP, Vos JM, Lunn MP, Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. BRIT J HAEMATOL 2017;176 (5):728-742 [PubMed]
  • Franssen LE, Roeven MWH, Hobo W, Doorn R, Oostvogels R, Falkenburg JHF, van de Donk NW, Kester MGD, Fredrix H, Westinga K, Slaper-Cortenbach I, Spierings E, Kersten MJ , Dolstra H, Mutis T, Schaap N, Lokhorst HM, A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma. BONE MARROW TRANSPL 2017;52 (10):1378-1383 [PubMed]
  • Minnema MC, Kimby E, D'Sa S, Fornecker LM, Poulain S, Snijders TJ, Kastritis E, Kremer S, Fitsiori A, Simon L, Davi F, Lunn M, Castillo JJ, Patterson CJ, Le Garff-Tavernier M, Costopoulos M, Leblond V, Kersten MJ, Dimopoulos MA, Treon SP, Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. HAEMATOLOGICA 2017;102 (1):43-51 [PubMed]
  • Persoon S, Chinapaw MJM, Buffart LM, Liu RDK, Wijermans P, Koene HR, Minnema MC, Lugtenburg PJ, Marijt EWA, Brug J, Nollet F, Kersten MJ, Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the EXIST study. PLOS ONE 2017;12 (7):e0181313 [PubMed]
  • Persoon S, Kersten MJ, Buffart LM, Vander Slagmolen G, Baars JW, Visser O, Manenschijn A, Nollet F, Chinapaw MJM, Health-related physical fitness in patients with multiple myeloma or lymphoma recently treated with autologous stem cell transplantation. J SCI MED SPORT 2017;20 (2):116-122 [PubMed]
  • Stevens WBC, Mendeville M, Redd R, Clear AJ, Bladergroen R, Calaminici M, Rosenwald A, Hoster E, Hiddemann W, Gaulard P, Xerri L, Salles G, Klapper W, Pfreundschuh M, Jack A, Gascoyne RD, Natkunam Y, Advani R, Kimby E, Sander B, Sehn LH, Hagenbeek A, Raemaekers J, Gribben J, Kersten MJ, Ylstra B, Weller E, de Jong D, Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. HAEMATOLOGICA 2017;102 (8):1413-1423 [PubMed]
  • Stuiver MM, Kampshoff CS, Persoon S, Groen W, van Mechelen W, Chinapaw MJM, Brug J, Nollet F, Kersten MJ, Schep G, Buffart LM, Validation and Refinement of Prediction Models to Estimate Exercise Capacity in Cancer Survivors Using the Steep Ramp Test. ARCH PHYS MED REHAB 2017;98 (11):2167-2173 [PubMed]
  • van Andel H, Kocemba KA, de Haan-Kramer A, Mellink CH, Piwowar M, Broijl A, van Duin M, Sonneveld P, Maurice MM, Kersten MJ , Spaargaren M, Pals ST, Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease. ONCOGENE 2017;36 (15):2105-2115 [PubMed]
  • van Andel H, Ren Z, Koopmans I, Joosten SPJ, Kocemba KA, de Lau W, Kersten MJ, de Bruin AM, Guikema JEJ, Clevers H, Spaargaren M, Pals ST, Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins. P NATL ACAD SCI USA 2017;114 (2):376-381 [PubMed]
  • Vos JM, Tsakmaklis N, Patterson CJ, Meid K, Castillo JJ, Brodsky P, Ganz T, Pals ST, Kersten MJ, Xu L, Yang G, Treon SP, Hunter ZR, CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib. HAEMATOLOGICA 2017;102 (11):e452-e455 [PubMed]
  • Younes A, Ansell S, Fowler N, Wilson W, de Vos S, Seymour J, Advani R, Forero A, Morschhauser F, Kersten MJ, Tobinai K, Zinzani PL, Zucca E, Abramson J, Vose J, The landscape of new drugs in lymphoma. NAT REV CLIN ONCOL 2017;14 (6):335-346 [PubMed]


  • Broijl A, Kersten MJ, Alemayehu WG, Levin MD, de Weerdt O, Vellenga E, Meijer E, Wittebol S, Tanis BC, Cornelisse PB, Stevens-Kroef M, Bos GMJ, Wijermans PW, Lokhorst H, Sonneveld P, Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma. HAEMATOLOGICA 2016;101 (4):e149-e152 [PubMed]
  • de Jong A, Kwee TC, Quarles van Ufford HME, Beek FJA, Quekel LGBA, de Klerk JMH, Zijlstra JM, Fijnheer R, Ludwig I, Kersten MJ, Stoker J, Nievelstein RAJ, Computed Tomography Observer Agreement in Staging Malignant Lymphoma. J COMPUT ASSIST TOMO 2016;40 (2):261-265 [PubMed]
  • de Rooij MFM, Kuil A, Kraan W, Kersten MJ, Treon SP, Pals ST, Spaargaren M, Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia. HAEMATOLOGICA 2016;101 (3):e111-e115 [PubMed]
  • Heijink DM, Kater AP , Hazenberg MD, Hagenbeek A, Kersten MJ, T-cells fighting B-cell lymphoproliferative malignancies: the emerging field of CD19 CAR T-cell therapy. NETH J MED 2016;74 (4):147-151 [PubMed]
  • Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG [Contributors: Spencer A, Grigg A, He S, Joshua D, Greil R, Kühr T, Linkesch W, Sormann S, Ludwig H, Robin V, Schots H, Vekemans MC, Wu KL, Doyen C, Song K, Reiman A, Shustik C, Bahlis N, Sandhu I, Xu Y, Jin J, Pour L, Ščudla V, Gregora E, Hájek R, Maisnar V, Andersen N, Gimsing P, Gregersen H, Facon T, Moreau P, Garderet L, Stoppa AM, Escoffre-Barbe M, Marit G, Benboubker L, Cartron G, Attal M, Jaccard A, Arnulf B, Fenk R, Langer C, Salwender HJ, Schmidt B, Illés Á, Masszi T, Jakucs J, Ben-Yehuda D, Braester A, Avivi I, Benyamini N, Hardan I, Nagler A, Shvetz O, Trestman S, Magen-Nativ H, Aversa F, Bosi A, Cavo M, Ferrara F, Liberati AM, Palumbo A, de Fabritis P, Fattori PP, Chou T, Handa H, Izumi T, Matsumoto M, Komeno T, Suzuki K, Kizaki M, Nakaseko C, Aotsuka N, Miyazaki K, Okamoto S, Nagai H, Iida S, Tsudo M, Kaneko H, Sunami K, Kubonishi S, Kiguchi T, Ozaki S, Uike N, Ishida T, Lee JH, Kim K, Kersten MJ, Zweegman S, Vellenga E, Minnema MC, Ganly PS, Simpson DR, Berkahn LC, Romeril KR, Baker BW, Corbett G, Jackson S, Grosicki S, Grząsko N, Hellmann A, Pluta A, Robak T, Geraldes C, Viterbo L, Borșaru G, Bumbea H, Gheorghita E, Shmidt A, Alexeeva J, Korobkin A, Podoltseva E, Pristupa A, Samoilova O, Mendeleeva L, Kaplanov K, Chng WJ, Goh YT, Espinosa MC, Echeveste MA, Gayoso J, Granell M, Mateos MV, Rosiñol L, Blimark C, Gruber A, Hansson M, Nahi H, Beksaç M, Basu S, Jenner MW, Marron G, Williams C, Sati H, Tighe J, Cavet J, Bensinger W, Hamadani M, Kanate A, Richardson P, Hari P, Charu V, Kumar S, Moreb JS, Siegel D, Irwin DH, Stuart R, Fonseca G, Nazir T, Oyola R, Hermann R, Catchatourian R, Hyzinski M, Liu H, Holstein S]] , Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. NEW ENGL J MED 2016;374 (17):1621-1634 [PubMed]
  • Nijland ML, Kersten MJ, Pals ST, Bemelman FJ, ten Berge IJM, Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. TRANSPLANT DIRECT 2016;2 (1):e48 [PubMed]
  • Pals ST, Kersten MJ, Spaargaren M, Targeting cell adhesion and homing as strategy to cure Waldenström's macroglobulinemia. BEST PRACT RES CL HA 2016;29 (2):161-168 [PubMed]
  • Thijssen R. The interplay between microenvironmental signaling and novel targeted drugs in CLL. S.l.: s.n.; 2016. 171p. ISBN 978-94-6182-733-3 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Eldering EF, Kater AP; copromotor(s): Kersten MJ)
  • Thijssen R, ter Burg J, Garrick B, van Bochove GGW, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IAM, van Kampen RJW, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP, Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. BLOOD 2016;128 (4):574-583 [PubMed]
  • Thijssen R, ter Burg J, van Bochove GGW, de Rooij MFM, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MHJ, Eldering E, Kersten MJ , Kater AP, The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. LEUKEMIA 2016;30 (2):337-345 [PubMed]
  • Thijssen R, ter Burg J, van Bochove GGW, de Rooij MFM, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MHJ, Eldering E, Kersten MJ , Kater AP, The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 ( voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells (Vol 30, pg 337, 2016). LEUKEMIA 2016;30 (9):1963 [PubMed]
  • van Dalen EC, Mank A, Leclercq E, Mulder RL, Davies M, Kersten MJ, van de Wetering MD, Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. COCHRANE DB SYST REV 2016;2016 (4):CD006247 [PubMed]
  • Vos JM, Gustine J, Rennke HG, Hunter Z, Manning RJ, Dubeau TE, Meid K, Minnema MC, Kersten MJ, Treon SP, Castillo JJ, Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. BRIT J HAEMATOL 2016;175 (4):623-630 [PubMed]
  • Vos JMI, Kersten MJ, Kraan W, Groeneveld ON, Linn C, Pals ST, Minnema MC, Effective treatment of Bing-Neel Syndrome with oral fludarabine: a case series of four consecutive patients. BRIT J HAEMATOL 2016;172 (3):461-464 [PubMed]
  • Zijlstra JM, Burggraaff CN, Kersten MJ, Barrington SF, FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?. HAEMATOLOGICA 2016;101 (11):1279-1283 [PubMed]


  • de Rooij MFM, Kuil A, Kater AP, Kersten MJ, Pals ST, Spaargaren M, Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. BLOOD 2015;125 (14):2306-2309 [PubMed]
  • Hengeveld PJ, Kersten MJ, B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?. BLOOD CANCER J 2015;5:e282 [PubMed]
  • Jak M, Kersten MJ, Behandeling van het non-hodgkin-lymfoom met antistoffen: nieuwe targets, nieuwe concepten. NED TIJDSCHR HEMATOL 2015;12 (7):245-252
  • Kersten MJ, Guikema JEJ, MYC in diffuse large B-cell lymphoma: always the bad guy?. LEUKEMIA LYMPHOMA 2015;56 (11):3003-3004 [PubMed]
  • Kersten MJ, Visser O, Schouten H, Zweegman S, Oudere patiënten hebben baat bij nieuwe middelen. MED CONTACT 2015;70 (dec):11-13
  • Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P, Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival. HAEMATOLOGICA 2015;100 (12):e508-e510 [PubMed]
  • Mank APM, Schoonenberg C, Bleeker K, Heijmenberg S, Heer Kd, van Oers MHJ, Kersten MJ, Early discharge after high dose chemotherapy is safe and feasible: a prospective evaluation of 6 years of home care. LEUKEMIA LYMPHOMA 2015;56 (7):2098-2104 [PubMed]
  • Sonneveld P, Asselbergs E, Zweegman S, van der Holt B, Kersten MJ, Vellenga E, van Marwijk-Kooy M, Broyl A, de Weerdt O, Lonergan S, Palumbo A, Lokhorst H, Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. BLOOD 2015;125 (3):449-456 [PubMed]
  • Vermaat JS, Pals ST, Younes A, Dreyling M, Federico M, Aurer I, Radford J, Kersten MJ, Precision medicine in diffuse large B-cell lymphoma: hitting the target. HAEMATOLOGICA 2015;100 (8):989-993 [PubMed]
  • Zweegman S, Lokhorst HM, Levin MD, de Waal E, Bos GMJ, Kersten MJ , Croockewit A, Ypma PF, Klein SK, Minnema MC, Sonneveld P, Richtlijn behandeling multipel myeloom 2015. NED TIJDSCHR HEMATOL 2015;12 (8):279-302


  • Adams HJA, Kwee TC, Lokhorst HM, Westerweel PE, Fijnheer R, Kersten MJ, Verkooijen HM, Stoker J, Nievelstein RAJ, Potential prognostic implications of whole-body bone marrow MRI in diffuse large B-cell lymphoma patients with a negative blind bone marrow biopsy. J MAGN RESON IMAGING 2014;39 (6):1394-1400 [PubMed]
  • de Jong A, Kwee TC, de Klerk JMH, Adam JA, de Keizer B, Fijnheer R, Kersten MJ, Ludwig I, Jauw YWS, Zijlstra JM, Pieters-van den Bos IC, Stoker J, Hoekstra OS, Nievelstein RAJ, Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma. AM J NUCL MED MOL IMAGING 2014;4 (3):231-238 [PubMed]
  • Hart A, Baars JW, Kersten MJ , Brandsma D, van Tinteren H, de Jong D, Spiering M, Dewit L, Boogerd W, Outcome of patients with primary central nervous system lymphoma treated outside clinical trials. NETH J MED 2014;72 (4):218-223 [PubMed]
  • Kersten MJ , Kraan W, Doorduijn J, Bromberg J, Lam K, Kluin PM, van der Holt BJ, Spaargaren M, Pals ST, Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations. BLOOD CANCER J 2014;4:e266 [PubMed]
  • Kraan W, van Keimpema M, Horlings HM, Schilder-Tol EJM, Oud MECM, Noorduyn LA, Kluin PM, Kersten MJ , Spaargaren M, Pals ST, High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. LEUKEMIA 2014;28 (3):719-720 [PubMed]
  • Kwee TC, Vermoolen MA, Akkerman EA, Kersten MJ, Fijnheer R, Ludwig I, Beek FJA, van Leeuwen MS, Bierings MB, Bruin MCA, Zsíros J, Quarles van Ufford HME, de Klerk JMH, Adam J, Stoker J, Uiterwaal CS, Nievelstein RAJ, Whole-body MRI, including diffusion-weighted imaging, for staging lymphoma: comparison with CT in a prospective multicenter study. J MAGN RESON IMAGING 2014;40 (1):26-36 [PubMed]
  • Sander B, de Jong D, Rosenwald A, Xie W, Balagué O, Calaminici M, Carreras J, Gaulard P, Gribben J, Hagenbeek A, Kersten MJ, Molina TJ, Lee A, Montes-Moreno S, Ott G, Raemaekers J, Salles G, Sehn L, Thorns C, Wahlin BE, Gascoyne RD, Weller E, The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. HAEMATOLOGICA 2014;99 (4):715-725 [PubMed]
  • Scheid C, Sonneveld P, Schmidt-Wolf IGH, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM, Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. HAEMATOLOGICA 2014;99 (1):148-154 [PubMed]
  • Thielen N, van der Holt B, Verhoef GEG, Ammerlaan RAHM, Sonneveld P, Janssen JJWM, Deenik W, Falkenburg JHF, Kersten MJ , Sinnige HAM, Schipperus M, Schattenberg A, van Marwijk Kooy R, Smit WM, Chu IWT, Valk PJM, Ossenkoppele GJ, Cornelissen JJ, Hoge dosis imatinib versus hoge dosis imatinib in combinatie met intermediaire dosis cytarabine bij patienten met nieuw gediagnosticeerde chronische myeloïde leukemie. NED TIJDSCHR HEMATOL 2014;11 (3):113


  • Adams HJA, Kwee TC, Vermoolen MA, de Keizer B, de Klerk JMH, Adam JA, Fijnheer R, Kersten MJ, Stoker J, Nievelstein RAJ, Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. EUR RADIOL 2013;23 (8):2271-2278 [PubMed]
  • Klodzinska S, Vos JMI, Kersten MJ , Wijermans P, Minnema MC, A survey on diagnostic methods and treatment strategies used in patients with Waldenström's macroglobulinaemia in The Netherlands. NETH J MED 2013;71 (2):90-96 [PubMed]
  • Kocemba KA, van Andel H, de Haan-Kramer A, Mahtouk K, Versteeg R, Kersten MJ , Spaargaren M, Pals ST, The hypoxia target adrenomedullin is aberrantly expressed in multiple myeloma and promotes angiogenesis. LEUKEMIA 2013;27 (8):1729-1737 [PubMed]
  • Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJM, Oud MECM, Scheepstra C, Kluin PM, Kersten MJ , Spaargaren M, Pals ST, High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. BLOOD CANCER J 2013;3:e139 [PubMed]
  • Mank APM. High dose treatment for haematologic malignancies. From rituals to evidence based practice. s.l.: s.n.; 2013. 215p. ISBN 9789461900296 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Oers MHJ; copromotor(s): Kersten MJ)
  • Persoon S, Kersten MJ, van der Weiden K, Buffart LM, Nollet F, Brug J, Chinapaw MJM, Effects of exercise in patients treated with stem cell transplantation for a hematologic malignancy: a systematic review and meta-analysis. CANCER TREAT REV 2013;39 (6):682-690 [PubMed]
  • Thielen N, van der Holt B, Verhoef GEG, Ammerlaan RAHM, Sonneveld P, Janssen JJWM, Deenik W, Falkenburg JHF, Kersten MJ, Sinnige HAM, Schipperus M, Schattenberg A, van Marwijk Kooy R, Smit WM, Chu IWT, Valk PJM, Ossenkoppele GJ, Cornelissen JJ, High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group. ANN HEMATOL 2013;92 (8):1049-1056 [PubMed]
  • van Dop WA, Kersten MJ, de Wever B, Hovius JW, Seronegative lyme neuroborreliosis in a patient using rituximab. BMJ CASE REP 2013;2013 (-):bcr2012007627 [PubMed]
  • Vos JMI, Minnema MC, Wijermans PW, Croockewit S, Chamuleau MED, Pals ST, Klein SK, Delforge M, van Imhoff GW, Kersten MJ, Guideline for diagnosis and treatment of Waldenström's macroglobulinaemia. NETH J MED 2013;71 (2):54-62 [PubMed]


  • Chinapaw MJM, Buffart LM, van Mechelen W, Schep G, Aaronson NK, van Harten WH, Stuiver MM, Kersten MJ, Nollet F, Kaspers GJL, van Dulmen-den Broeder E, Huisman J, Takken T, van Tulder M, Brug J, Alpe d'HuZes Cancer Rehabilitation (A-CaRe) Research: Four Randomized Controlled Exercise Trials and Economic Evaluations in Cancer Patients and Survivors. INT J BEHAV MED 2012;19 (2):143-156 [PubMed]
  • Kersten MJ , Doorduijn JK, de Jong D, Zijlstra-Baalbergen JM, Ghidey W, Spiering M, Steijaert M, Meulendijks I, Hagenbeek A, ReBel studie: een gerandomiseerde fase I/II studie naar de effectiviteit en veiligheid van behandeling met lenalidomide en rituximab, met of zonder bendamustine, bij volwassen patienten met recidief folliculair lymfoom. NED TIJDSCHR HEMATOL 2012;9:71
  • Kocemba KA, Groen RWJ, van Andel H, Kersten MJ, Mahtouk K, Spaargaren M, Pals ST, Transcriptional Silencing of the Wnt-Antagonist DKK1 by Promoter Methylation Is Associated with Enhanced Wnt Signaling in Advanced Multiple Myeloma. PLOS ONE 2012;7 (2):e30359 [PubMed]
  • Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Janssen JJ, Zijlmans M, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P, Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. BLOOD 2012;119 (26):6219-6225 [PubMed]
  • Sonneveld P, Schmidt-Wolf IGH, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GMJ, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM, Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial. J CLIN ONCOL 2012;30 (24):2946-2955 [PubMed]
  • Tonino SH, van de Berg PJ, Yong SL, ten Berge IJ, Kersten MJ, van Lier RAW, van Oers MH, Kater AP, Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia. LEUKEMIA LYMPHOMA 2012;53 (9):1785-1794 [PubMed]
  • van Dalen EC, Mank A, Leclercq E, Mulder RL, Davies M, Kersten MJ, van de Wetering MD, Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. COCHRANE DB SYST REV 2012;2012 (9):CD006247 [PubMed]
  • van Maldegem F, Wormhoudt TAM, Mulder MMS, Oud MECM, Schilder-Tol E, Musler AR, Aten J, Saeed P, Kersten MJ , Pals ST, van Noesel CJM, Bende RJ, Chlamydia psittaci-negative ocular adnexal marginal zone B-cell lymphomas have biased V(H)4-34 immunoglobulin gene expression and proliferate in a distinct inflammatory environment. LEUKEMIA 2012;26 (7):1647-1653 [PubMed]
  • Vos JM, Minnema MC, Wijermans PW, Croockewit S, Chamuleau ME, Pals ST, Klein SK, Delforge M, van Imhoff GW, Kersten MJ, Richtlijn voor diagnostiek en behandeling van de ziekte van Waldenström. NED TIJDSCHR HEMATOL 2012;9:219
  • Zweegman S, Lokhorst HM, Levin MD, de Waal E, Bos GM, Kersten MJ , Ypma P, Klein SK, Minnema MC, Sonneveld P, Richtlijnen behandeling multipel myeloom 2012. NED TIJDSCHR HEMATOL 2012;9:300


  • Groen RWJ, de Rooij MFM, Kocemba KA, Reijmers RM, de Haan-Kramer A, Overdijk MB, Aalders L, Rozemuller H, Martens ACM, Bergsagel PL, Kersten MJ, Pals ST, Spaargaren M, N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation. HAEMATOLOGICA 2011;96 (11):1653-1661 [PubMed]
  • Hommes DW, Duijvestein M, Zelinkova Z, Stokkers PCF, Ley MHd, Stoker J, Voermans C, van Oers MHJ, Kersten MJ, Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease. J CROHNS COLITIS 2011;5 (6):543-549 [PubMed]
  • Kersten MJ, Radioimmunotherapy in follicular lymphoma: Some like it hot…. TRANSFUS APHER SCI 2011;44 (2):173-178 [PubMed]
  • Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, Cornelissen JJ, Janssen JJ, Huisman C, Cornelisse PB, Bruijnen CP, Emmelot M, Sonneveld P, Lokhorst HM, Mutis T, Minnema MC, Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. BLOOD 2011;118 (9):2413-2419 [PubMed]
  • Kwee TC, Akkerman EM, Fijnheer R, Kersten MJ, Zsíros J, Ludwig I, Bierings MB, Vermoolen MA, van Leeuwen MS, Stoker J, Nievelstein RAJ, MRI for staging lymphoma: whole-body or less?. J MAGN RESON IMAGING 2011;33 (5):1144-1150 [PubMed]
  • Liu RDK, Buffart LM, Kersten MJ, Spiering M, Brug J, van Mechelen W, Chinapaw MJM, Psychometric properties of two physical activity questionnaires, the AQuAA and the PASE, in cancer patients. BMC MED RES METHODOL 2011;11:30 [PubMed]
  • Mank A, van der Lelie J, de Vos R, Kersten MJ, Safe early discharge for patients undergoing high dose chemotherapy with or without stem cell transplantation: a prospective analysis of clinical variables predictive for complications after treatment. J CLIN NURS 2011;20 (3-4):388-395 [PubMed]
  • Minnema MC, van Dorp S, van de Donk NWCJ, Schouten F, Kersten MJ , Coenen JLLM, Schouten H, Zweegman S, Schaafsma R, Lokhorst HM, Prognostic factors and outcome in relapsed multiple myeloma after nonmyeloablative allo-SCT: a single center experience. BONE MARROW TRANSPL 2011;46 (2):244-249 [PubMed]
  • Persoon S, Kersten MJ , Chinapaw MJM, Brug J, Nollet F, EXercise Intervention after Stem cell Transplantation (EXIST). NED TIJDSCHR HEMATOL 2011;8 (3):125-129
  • Ruinemans-Koerts J, Boonstra JG, Klasen IS, Zweegman S, Minnema MC, Wegman JJ, Kersten MJ , Dinkelaar RB, Wijermans P, Raymakers RAP, Laboratoriumonderzoek bij monoklonale gammopathie: detectie van monoklonale immuunglobulinen. NED TIJDSCHR HEMATOL 2011;8 (4):160
  • Thai KTD, Wismeijer JA, Zumpolle C, de Jong MD, Kersten MJ , de Vries PJ, High incidence of peripheral blood plasmacytosis in patients with dengue virus infection. CLIN MICROBIOL INFEC 2011;17 (12):1823-1828 [PubMed]
  • Tuinman PR, Nieuwenhuis MBB, Groen E, Kersten MJ, A young woman with generalised lymphadenopathy. Systemic lupus erythematosus (SLE). NETH J MED 2011;69 (6):284-288 [PubMed]
  • van Oers MHJ, Kersten MJ, Treatment strategies in advanced stage follicular lymphoma. BEST PRACT RES CL HA 2011;24 (2):187-201 [PubMed]
  • Vermoolen MA, Kersten MJ, Fijnheer R, van Leeuwen MS, Kwee TC, Nievelstein RAJ, Magnetic resonance imaging of malignant lymphoma. EXPERT REV HEMATOL 2011;4 (2):161-171 [PubMed]
  • Zweegman S, Minnema MC, Stevens-Kroef M, Kersten MJ , Wijermans P, Wegman JJ, Regelink JC, Brooimans RA, Beverloo B, Bloem AC, Lokhorst HM, Sonneveld P, Raymakers RAP, Diagnostiek bij multipel myeloom: de rol van beeldvorming, chromosoomanalyse en multiparameterflowcytometrie. NED TIJDSCHR HEMATOL 2011;8 (4):146


  • Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, Bertsch U, Buijs A, Stevens-Kroef M, Beverloo HB, Vellenga E, Zweegman S, Kersten MJ, van der Holt B, el Jarari L, Mulligan G, Goldschmidt H, van Duin M, Sonneveld P, Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. BLOOD 2010;116 (14):2543-2553 [PubMed]
  • Deenik W, Janssen JJWM, van der Holt B, Verhoef GEG, Smit WM, Kersten MJ, Daenen SMGJ, Verdonck LF, Ferrant A, Schattenberg AVMB, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Beverloo HB, Löwenberg B, Valk PJM, Ossenkoppele GJ, Cornelissen JJ, Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. HAEMATOLOGICA 2010;95 (6):914-921 [PubMed]
  • Khajouei R, Peek N, Wierenga PC , Kersten MJ , Jaspers MWM, Effect of predefined order sets and usability problems on efficiency of computerized medication ordering. INT J MED INFORM 2010;79 (10):690-698 [PubMed]
  • Kneppers E, Lokhorst HM, Eeltink CM, Huls G, Kersten MJ, Koedam J, Minnema MC, van Oers MHJ, Raymakers RAP, Schaafsma MR, Vellenga E, Wijermans PW, Wittebol S, Sonneveld P, Zweegman S, Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program. CL LYMPH MYELOM LEUK 2010;10 (2):138-143 [PubMed]
  • Lokhorst HM, von dem Borne PA, Kersten MJ, HOVON 108: T-cel-gedepleteerde niet-myeloablatieve allogene stamceltransplantatie gevolgd door vroege consolidatie met lenalidomide of lenalidomide gecombineerd met bortezomib en aanvullend donorlymfocyteninfusie voor patiënten met een eerste recidief of progressie na eerstelijnsbehandeling. NED TIJDSCHR HEMATOL 2010;7 (8):332-338
  • Persoon S, Kersten MJ, Chinapaw MJM, Buffart LM, Burghout H, Schep G, Brug J, Nollet F, Design of the EXercise Intervention after Stem cell Transplantation (EXIST) study: a randomized controlled trial to evaluate the effectiveness and cost-effectiveness of a individualized high intensity physical exercise program on fitness and fatigue in patients with multiple myeloma or (non-) Hodgkin's lymphoma treated with high dose chemotherapy and autologous stem cell transplantation. BMC CANCER 2010;10 (1):671 [PubMed]
  • Vlaar APJ, Porcelijn L, van Rooijen-Schreurs IHM, Lardy NM, Kersten MJ, Juffermans NP, The divergent clinical presentations of transfusion-related acute lung injury illustrated by two case reports. MED SCI MONITOR 2010;16 (10):CS129-CS134 [PubMed]


  • Heutte N, Flechtner HH, Mounier N, Mellink WAM, Meerwaldt JH, Eghbali H, van't Veer MB, Noordijk EM, Kluin-Nelemans JC, Lampka E, Thomas J, Lugtenburg PJ, Viterbo L, Carde P, Hagenbeek A, van der Maazen RW, Smit WGJM, Brice P, van Marwijk Kooy M, Baars JW, Poortmans P, Tirelli U, Leeksma OC, Tomsic R, Feugier P, Salles G, Gabarre J, Kersten MJ, van den Neste E, Creemers GJM, Gaillard I, Meijnders P, Tertian G, Reman O, Muller HP, Troncy J, Blanc M, Schroyens W, Voogt PJ, Wijermans P, Rieux C, Fermé C, Henry-Amar M, Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. LANCET ONCOL 2009;10 (12):1160-1170 [PubMed]
  • Kager LM, Kersten MJ, Kloppenborg RP, van Oers R, van den Born BJ, Reversible posterior leucoencephalopathy syndrome associated with bortezomib in a patient with relapsed multiple myeloma. BMJ CASE REP 2009;2009:bcr06.2009.1926 [PubMed]


  • Choi G, van den Borne MPJ, Visser CE, Kersten MJ, Kater AP, Invasive infections with a coagulase-negative staphylococcus in an immunocompromised patient: case report and review of the literature. ANN HEMATOL 2008;87 (9):771-772 [PubMed]
  • Deenik W, van der Holt B, Verhoef GEG, Smit WM, Kersten MJ, Kluin-Nelemans HC, Verdonck LF, Ferrant A, Schattenberg AVMB, Janssen JJWM, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Westveer PHM, Beverloo HB, Valk P, Löwenberg B, Ossenkoppele GJ, Cornelissen JJ, Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. BLOOD 2008;111 (5):2581-2588 [PubMed]
  • de Gorter DJJ, Reijmers RM, Beuling EA, Naber HPH, Kuil A, Kersten MJ, Pals ST, Spaargaren M, The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells. BLOOD 2008;111 (7):3364-3372 [PubMed]
  • Lokhorst HM, Zweegman S, Kersten MJ , Raymakers RAP, Vellenga E, Wittebol S, Sonneveld P, Richtlijnen behandeling multipel myeloom anno 2008. NED TIJDSCHR HEMATOL 2008;5 (4):150
  • Minnema MC, van de Donk NWCJ, Zweegman S, Hegenbart U, Schonland S, Raymakers R, Zijlmans JMJM, Kersten MJ , Bos GMJ, Lokhorst HM, Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. BONE MARROW TRANSPL 2008;41 (9):779-784 [PubMed]
  • van Gent R, Kater AP, Otto SA, Jaspers A, Borghans JAM, Vrisekoop N, Ackermans MAT, Ruiter AFC, Wittebol S, Eldering E, van Oers MHJ, Tesselaar K, Kersten MJ, Miedema F, In vivo Dynamics of Stable Chronic Lymphocytic Leukemia Inversely Correlate with Somatic Hypermutation Levels and Suggest No Major Leukemic Turnover in Bone Marrow. CANCER RES 2008;68 (24):10137-10144 [PubMed]
  • Wever PC, Bos JC, van den Brekel MWM, de Jong D, Bovée LPMJ, Kersten MJ , Schellekens JFP, Kerst JM, Een waarschijnlijk geval van difterie. TIJDSCHR INFECTIEZIEKTEN 2008;3 (6):230-235


  • Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE, Wessels LA, van Laar R, van Krieken JHJM, Baars JW, Raemaekers J, Kluin PM, van't Veer LJ, de Jong D, Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J CLIN ONCOL 2007;25 (4):390-398 [PubMed]
  • Kerst JM, Heisterkamp S, de Jong D, Haas RLM, Kersten MJ, Nieuwe ontwikkelingen in de diagnostiek en primaire behandeling van indolent folliculair non-hodgkinlymfoom. NED TIJDSCHR HEMATOL 2007;4 (7):244-250
  • Klein SK, Kersten MJ, Rituximab: standaardtherapie bij non-Hodgkin lymfoom. TIJDSCHR KANKER 2007;31:20
  • Rijneveld AW, Koene HR, Kersten MJ, Maligne lymfomen bij patienten met een hiv-infectie. TIJDSCHR INFECTIEZIEKTEN 2007;2 (6):202-208
  • Rijneveld AW, Koene HR, Kersten MJ, Maligne lymfomen bij patienten met immuundeficientie ten gevolge van een hiv-infectie. NED TIJDSCHR HEMATOL 2007;4 (6):204-209


  • Deloose STP, Smit LA, Pals FT, Kersten MJ, van Noesel CJM, Pals ST, High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. LEUKEMIA 2005;19 (5):851-855 [PubMed]
  • Gallegos Ruiz MI, van Oers MHJ, Kersten MJ, Rituximab: de 'magic bullet' in de bestrijding van het B-cel-non-Hodgkin-lymfoom? Werkingsmechanismen en mogelijke oorzaken van resistentie. NED TIJDSCHR HEMATOL 2005;2 (5):184-191
  • Glas AM, Kersten MJ, Delahaye LJMJ, Witteveen AT, Kibbelaar RE, Velds A, Wessels LFA, Joosten P, Kerkhoven RM, Bernards R, van Krieken JHJM, Kluin PM, van't Veer LJ, de Jong D, Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. BLOOD 2005;105 (1):301-307 [PubMed]
  • Hunting CB, Deloose STP, de Valk B, Kersten MJ, Ziekte van Castleman. NED TIJDSCHR HEMATOL 2005;2 (1):22-27
  • Juffermans NP, Jager A, Kersten MJ , van Oers MH, Hommes DW, Epstein-Barr-virus-gerelateerde lymfomen bij patiënten met inflammatoire darmziekte. NED TIJDSCHR GENEESKD 2005;149 (33):1859-1863 [PubMed]
  • Kersten MJ. Monoklonale antilichaamtherapie bij B-cel chronische lymfatische leukemie in: Ossenkoppele G, van de Loosdrecht AA, editors. Immuuntherapie van hematologische ziekten. Alphen aan de Rijn: van Zuiden Communications; 2005., p. 41-46
  • Kersten MJ, Rituximab immunotherapy in the treatment of B-cell non-Hodgkin's lymphoma. EUR J HOSP PHARM 2005;II (4):18-19


  • de Jong D, Glas A, Kersten MJ, Genexpressieprofilering bij lymfomen. NED TIJDSCHR HEMATOL 2004;- (3):106-112
  • Kersten MJ, de Jong D, Raemaekers JMM, Kluin PM, Hagenbeek A, Beyond the International Prognostic Index: new prognostic factors in follicular lymphoma and diffuse large-cell lymphoma A meeting report of the Second International Lunenburg Lymphoma Workshop. HEMATOL J 2004;5 (3):202-208 [PubMed]


  • de Gast GC, Batchelor D, Kersten MJ , Vyth-Dreese FA, Sein J, van de Kasteele WF, Nooijen WJ, Nieweg OE, de Waal MA, Boogerd W, Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma. BRIT J CANCER 2003;88 (2):175-180 [PubMed]
  • de Jong D, Glas AM, Boerrigter L, Hermus MC, Dalesio O, Willemse E, Nederlof PM, Kersten MJ, Very late relapse in diffuse large B-cell lymphoma represents clonally related disease and is marked by germinal center cell features. BLOOD 2003;102 (1):324-327 [PubMed]
  • Kok M, Bonfrer JM, Korse CM, de Jong D, Kersten MJ, Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma. TUMOR BIOL 2003;24 (1):53-60 [PubMed]
  • Koopmans RP, van den Born BJ, Kersten MJ , Hart W, Klinisch denken en beslissen in de praktijk. Een 41-jarige man met onbegrepen periodieke koorts. NED TIJDSCHR GENEESKD 2003;147 (37):1778-1783 [PubMed]
  • Verra N, Jansen R, Groenewegen G, Mallo H, Kersten MJ , Bex A, Vyth-Dreese FA, Sein J, van de Kasteele W, Nooijen WJ, de Waal M, Horenblas S, de Gast GC, Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. BRIT J CANCER 2003;88 (9):1346-1351 [PubMed]


  • Kersten MJ , van Oers RH, Management of AIDS-related non-Hodgkin's lymphomas. DRUGS 2001;61 (9):1301-1315 [PubMed]


  • de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ , Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH, Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. CLIN CANCER RES 2000;6 (4):1267-1272 [PubMed]
  • van Baarle D, Hovenkamp E, Dukers NH, Renwick N, Kersten MJ , Goudsmit J, Coutinho RA, Miedema F, van Oers MH, High prevalence of Epstein-Barr virus type 2 among homosexual men is caused by sexual transmission. J INFECT DIS 2000;181 (6):2045-2049 [PubMed]


  • Berger C, van Baarle D, Kersten MJ , Klein MR, Al-Homsi AS, Dunn B, McQuain C, van Oers R, Knecht H, Carboxy terminal variants of Epstein-Barr virus-encoded latent membrane protein 1 during long-term human immunodeficiency virus infection: reliable markers for individual strain identification. J INFECT DIS 1999;179 (1):240-244 [PubMed]
  • Kersten MJ , Surachno S, Koopman MG, van 't Veer LJ, Pals ST, van Oers MH, Epstein-Barr-virus in een donornier als oorzaak van non-Hodgkin-lymfoom. NED TIJDSCHR GENEESKD 1999;143 (7):360-364 [PubMed]
  • van Baarle D, Hovenkamp E, Kersten MJ , Klein MR, Miedema F, van Oers MH, Direct Epstein-Barr virus (EBV) typing on peripheral blood mononuclear cells: no association between EBV type 2 infection or superinfection and the development of acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. BLOOD 1999;93 (11):3949-3955 [PubMed]


  • Al-Homsi AS, Berger C, van Baarle D, Kersten MJ , Klein MR, McQuain C, van Oers R, Knecht H, Molecular analysis of critical sequences within the EBNA-2 type 1 gene from Epstein-Barr virus isolates from patients with infectious mononucleosis, tonsillar hyperplasia, and HIV infection. INT J MOL MED 1998;1 (6):983-987 [PubMed]
  • Kersten MJ , van Gorp J, Pals ST, Boon F, van Oers MH, Expression of Epstein-Barr virus latent genes and adhesion molecules in AIDS-related non-Hodgkin's lymphomas: correlation with histology and CD4-cell number. LEUKEMIA LYMPHOMA 1998;30 (5-6):515-524 [PubMed]
  • Kersten MJ , Verduyn TJ, Reiss P, Evers LM, de Wolf F, van Oers MH, Treatment of AIDS-related non-Hodgkin's lymphoma with chemotherapy (CNOP) and r-hu-G-CSF: clinical outcome and effect on HIV-1 viral load. ANN ONCOL 1998;9 (10):1135-1138 [PubMed]


  • Feltkamp MC, Kersten MJ , van der Lelie J, Burggraaf JD, de Hoog GS, Kuijper EJ, Fatal Scedosporium prolificans infection in a leukemic patient. EUR J CLIN MICROBIOL 1997;16 (6):460-464 [PubMed]
  • Kersten MJ , de Jong S, Evers LM, Koene HR, van Oers MH, Addition of granulocyte colony-stimulating factor to chemotherapy in patients with AIDS-related lymphoma: effects on neutrophil Fc gamma receptor expression and soluble Fc gammaRIII plasma levels. BRIT J HAEMATOL 1997;99 (3):537-541 [PubMed]
  • Kersten MJ , Klein MR, Holwerda AM, Miedema F, van Oers MH, Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma. J CLIN INVEST 1997;99 (7):1525-1533 [PubMed]


  • Kersten MJ , Evers LM, Dellemijn PL, van den Berg H, Portegies P, Hintzen RQ, van Lier RA, von dem Borne AE, van Oers RH, Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies. BLOOD 1996;87 (5):1985-1989 [PubMed]
  • Kersten MJ , Lange R, Smeets ME, Vreugdenhil G, Roozendaal KJ, Lameijer W, Goudsmit R, Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. ANN HEMATOL 1996;73 (5):247-252 [PubMed]


  • Kersten MJ , Mertens MJ, Pals ST, Reiss P, van Oers MH, Met HIV samenhangend non-Hodgkin-lymfoom bij 45 patiënten; een retrospectieve analyse. NED TIJDSCHR GENEESKD 1993;137 (28):1396-1400 [PubMed]


  • Hollak CE, Kersten MJ , van der Lelie J, Lange JM, Thrombocytopenic purpura as first manifestation of human immunodeficiency virus type I (HIV-1) infection. NETH J MED 1990;37 (1-2):63-68 [PubMed]


  • Huisman MV, Büller HR, ten Cate JW, van Royen EA, Vreeken J, Kersten MJ , Bakx B, Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. CHEST 1989;95 (3):498-502 [PubMed]